Transformed B-cell Lymphoma : Clonal Evolution, Microenvironment Remodeling and Therapeutic Targets Discovery; Prospective Program (TYPHON-P)
The progression of small B-cell lymphomas toward a more aggressive histological form, specifically, diffuse large B-cell lymphoma (DLBCL) is a serious and most often fatal event. This process gives rise to several categories of scientific challenges :
- Anticipating this transformation through the early detection-while the disease is still in its indolent B-cell lymphoma stage-of biological markers that predict such a shift, particularly those that define tumor sub-clones at high risk of transformation.
- Identifying the specific event(s) that, within an ongoing and continuous process, trigger the definitive transition from the indolent B-cell lymphoma phase to the transformed B-cell lymphoma phase.
- Identifying the disrupted biological functions that drive treatment resistance in the transformed B-cell lymphoma stage, with the goal of defining new therapeutic targets.
Hypothesis :
- The aggressive transformation of indolent B-cell lymphomas results from an imbalance in the subclonal structure, driven by the evolution of a dominant subclone that undergoes aggressive transformation. This subclonal competition-occurring either spontaneously or under therapeutic pressure-is fueled by the acquisition and/or selection of specific molecular and epigenetic alterations, as well as favorable remodeling of the tumor microenvironment. Some of these changes are detectable as early as the indolent phase, offering the prospect of early detection, while others dictate the mechanisms of therapeutic resistance following transformation.
- Understanding the mechanisms of therapeutic resistance in transformed DLBCL could pave the way for the development of new, effective treatments. Furthermore, these insights could potentially be applied to resistant forms of de novo DLBCL-the most common category (40%) of B-cell lymphoma.
Our primary objective is to identify and validate the molecular, cellular, and microenvironmental alterations associated with therapeutic resistance in transformed B-cell lymphomas, and to investigate the presence of these mechanisms in resistant forms of de novo DLBCL.
Secondary objective 1. To understand the mechanisms underlying tumor evolution in each subtype of transformed B-cell lymphoma, with regard to both the characteristics of the tumor cell and its microenvironment.
Secondary objective 2. To develop cellular and animal models that mimic the transformed phase of indolent B-cell lymphomas.
Secondary objective 3. To identify biological characteristic, at the indolent B-cell lymphoma stag, that are predictive of aggressive transformation.
調査の概要
状態
介入・治療
- 他の:Identification of molecular and/or cellular signatures associated with the type of treatment response in patients with transformed B-cell lymphoma
- 他の:Identify, at the indolent/small-cell B-cell lymphoma stage, the biological characteristics that are predictive of aggressive transformation.
- 他の:investigate the existence of these mechanisms in resistant forms of de novo diffuse large B-cell lymphoma.
詳細な説明
TYPHON-P is a regional, multicenter, longitudinal, and translational observational study based on the prospectivebuilding of a clinical-biological cohort and a centralized biobank, managed by the Lorraine Biological Resource Center and the Pathology Department of the Nancy University Hospital. The study will include patients with indolent B-cell lymphoma, transformed B-cell lymphoma, or de novo aggressive B-cell lymphoma, as well as patients for whom a non-tumor tissue sample is available to serve as a technical reference.
Clinical, biological, therapeutic, and outcome data will be collected from medical records, and residual tissue samples originally obtained for routine clinical care will be processed according to standardized pre-analytical procedures and stored for future analysis.
The program comprises three complementary analytical sub-studies:
(i) a longitudinal, paired study comparing samples from the same patient at both the indolent and transformed stages, with the aim of characterizing the mechanisms of transformation; (ii) an investigation into the association between biological characteristics and therapeutic response within various groups of transformed B-cell lymphomas, with an exploration of whether these associations can be extrapolated to de novo diffuse large B-cell lymphoma (the most common lymphoma subtype, 15% of which exhibit therapeutic resistance); (iii) a prognostic study using samples obtained at the indolent stage to identify biological characteristics associated with the subsequent risk of transformation.
Analyses will be conducted separately for each lymphoma subtype, with Richter transformation and transformed follicular lymphoma serving as the primary models, while rarer forms will be the subject of exploratory analyses. Initial discovery-phase analyses will primarily relie on available retrospective samples. The identified biological findings and signatures will subsequently be evaluated within the prospective collection, following a pre-specified validation strategy. Longitudinal follow-up, planned for a maximum duration of ten years, will serve to document disease transformation, treatments received, therapeutic response, progression, and survival. Prospective samples will undergo standardized processing in a fresh state-including, wherever possible, the preparation of viable cell suspensions-to facilitate multi-omic, single-cell, spatial, and functional analyses, as well as the development of patient-derived models.
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前:Julien BROSÉUS, Professor
- 電話番号:+33 03 83 15 49 14
- メール:j.broseus@chru-nancy.fr
研究場所
-
-
-
Nancy、フランス、54000
- University Hospital of Nancy
-
コンタクト:
- Mylène VAUTROT, Project manager
- 電話番号:+33 03 83 15 54 56
- メール:m.vautrot@chru-nancy.fr
-
-
参加基準
適格基準
就学可能な年齢
- 子
- 大人
- 高齢者
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
The objective is to obtain a cohort of approximately 20 to 60 analyzable cases for each subtype of transformed B-cell lymphoma, enabling the exploration of molecular alterations associated with transformation, the study of mechanisms of therapeutic resistance, and the identification of biological signatures with theranostic relevance.
For technical and methodological reasons, a control group consisting of 20 non-tumor lymph node samples will be included in this study.
Recruitment objectives:
Recruitment target for the study group: 210 patients with transformed B-cell lymphoma
Recruitment targets for the 3 control subgroups:
- 210 patients for the group with untransformed indolent B-cell lymphoma
- 270 patients for the group with de novo diffuse large B-cell lymphoma
- 20 patients for the control group
説明
Case groups: transformed B-cell lymphomas
Inclusion Criteria:
Patients who benefited from medical care at the University Hospital of Nancy or the Regional Hospital of Metz
-with a history of, or a current diagnosis of, one of the following five types of indolent B-cell lymphoma: CLL: chronic lymphocytic leukemia FL: follicular lymphoma MZL: marginal zone lymphoma LPL: lymphoplasmacytic lymphoma MCL: mantle cell lymphoma
Patients in whom an aggressive B-cell lymphoma is suspected and for whom a diagnostic workup (including a tumor biopsy with histopathological analysis) is underway:
Richter transformation (RT) Transformed follicular lymphoma (tFL) Transformed marginal zone lymphoma (tMZL) Transformed lymphoplasmacytic lymphoma (tLPL) Blastoid mantle cell lymphoma
- Cases subsequently confirmed as one of the following histological variants: DLBCL (Diffuse Large B-Cell Lymphoma), Hodgkin lymphoma, or blastoid variant
- Cases for which biological samples potentially containing tumor cells are available and confirmed to contain a significant proportion of tumor cells (> 30%)
- Patients for whom at least one of the following types of samples is available:
Circulating blood cells, plasma, serum, any sample of cerebrospinal fluid, pleural fluid, or peritoneal fluid, biopsies performed for the diagnosis and follow-up of the lymphoma, cells extracted from these biopsies
Exclusion Criteria:
- Samples that do not meet the required diagnostic criteria
- Samples that do not meet the quality criteria necessary for analysis
- Samples that lack sufficient tumor content/representativeness for the requirements and analytical standards involved
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:PROSPECTIVE
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
Case group : Transformed B-cell lymphoma
Patients : - who benefited from medical care at the University Hospital of Nancy or the Regional Hospital of Metz Patients with a history of, or a current diagnosis of, one of the following five types of indolent B-cell lymphoma: CLL: chronic lymphocytic leukemia FL: follicular lymphoma MZL: marginal zone lymphoma LPL: lymphoplasmacytic lymphoma MCL: mantle cell lymphoma
|
Identification of molecular and/or cellular signatures associated with the type of treatment response in patients with transformed B-cell lymphoma-categorized as good responders (complete remission), partial responders, and non-responders (progression during treatment or primary refractory disease)-defined in a discovery cohort and subsequently validated in an independent cohort, with an assessment of effect size, reproducibility, and discriminative value. Performance of biological signatures, measured at the indolent stage, in predicting aggressive histological transformation during follow-up. This analysis will be conducted separately for each homogeneous subgroup of transformed B-cell lymphoma. Biological associations will be characterized by their effect size, their statistical significance-following correction for multiple comparisons-and their reproducibility in a validation cohort. Presence/absence of these molecular and/or cellular signatures correlated with therapeutic response in de novo DLBCL, and correlation with therapeutic response within this group. |
|
De novo aggressive lymphoma group (primarily de novo DLBCL)
Patients: - who benefited from medical care at the Nancy University Hospital or the Metz-Thionville Regional Hospital. Patients in whom a de novo aggressive B-cell lymphoma (DLBCL, Hodgkin lymphoma, or a blastoid variant) is suspected, and for whom a diagnostic workup-including a tumor biopsy with histopathological analysis-is currently underway
|
Presence/absence of these molecular and/or cellular signatures correlated with therapeutic response in de novo DLBCL, and correlation with therapeutic response within this group. |
|
Indolent/small-cell non-transformed B-cell lymphomas group
Patients :
|
Performance of biological signatures, measured at the indolent stage, in predicting aggressive histological transformation during follow-up. This analysis will be conducted separately for each homogeneous subgroup of transformed B-cell lymphoma. Biological associations will be characterized by their effect size, their statistical significance-following correction for multiple comparisons-and their reproducibility in a validation cohort. |
|
Non-tumor patient" control group / lymph node tissue and blood free of tumor cells
Patients:
|
Identification of molecular and/or cellular signatures associated with the type of treatment response in patients with transformed B-cell lymphoma-categorized as good responders (complete remission), partial responders, and non-responders (progression during treatment or primary refractory disease)-defined in a discovery cohort and subsequently validated in an independent cohort, with an assessment of effect size, reproducibility, and discriminative value. Performance of biological signatures, measured at the indolent stage, in predicting aggressive histological transformation during follow-up. This analysis will be conducted separately for each homogeneous subgroup of transformed B-cell lymphoma. Biological associations will be characterized by their effect size, their statistical significance-following correction for multiple comparisons-and their reproducibility in a validation cohort. Presence/absence of these molecular and/or cellular signatures correlated with therapeutic response in de novo DLBCL, and correlation with therapeutic response within this group. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
To identify and validate the molecular, cellular, and microenvironmental alterations associated with therapeutic resistance in transformed B-cell lymphomas, and to investigate the presence of these mechanisms in resistant forms of *de novo* DLBCLs
時間枠:10 years
|
Outcome measure 1 : correlation between gene expression profiles at agressive stage, and response to treatment. Measurement : whole transcriptome profiling by RNA-sequencing Unit of measure : transcripts rates Outcome measure 2 : correlation between protein expression profiles at agressive stage, and response to treatment. Measurement : protein expression by liquid chromatography coupled with mass spectrometry Unit of measure : copy numbers for each protein Outcome measure 3 : correlation between tumor microenvironment, and response to treatment. Measurement : microenvironment profiling by flow cytometry Unit of measure : comparative enrichment for each immune cell subtype (CD4+ T-cells, CD8+ T-cells, macrophages) Treatment responses : good responders (complete remission), partial responders, and non-responders (progression during treatment or primary refractory disease). Signatures will be defined in a discovery cohort and subsequently confirmed in an independent cohort. |
10 years
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Identify, at the indolent/small-cell B-cell lymphoma stage, the biological characteristics that are predictive of aggressive transformation.
時間枠:10 years
|
The analysis will be conducted separately for each homogeneous subgroup of transformed B-cell lymphoma. Outcome measure 1 : correlation between gene expression profiles at indolent stage, and the occurence of agressive transformation. Measurement : whole transcriptome profiling Measurement tool : RNA-sequencing Unit of measure : transcripts rates Outcome measure 2 : correlation between DNA methylation profiles at indolent stage, and the occurence of agressive transformation. Measurement : whole methylome profiling Measurement tool : long read whole genome sequencing Unit of measure : methylation rates for 28 billion sites Outcome measure 3 : correlation between proteomic profiles at indolent stage, and the occurence of agressive transformation. Measurement : protein expression Measurement tool : liquid chromatography coupled with mass spectrometry Unit of measure : absolute numbers for each protein |
10 years
|
|
Develop cellular and animal models that mimic the transformed phase of indolent B-cell lymphomas.
時間枠:10 years
|
Outcome measure 1 : gene expression profiles concordance between patient-derived experimental models and the original tumors. Measurement : whole transcriptome profiling by RNA-sequencing Unit of measure : rate of transcripts Outcome measure 2 : protein expression profiles concordance between patient-derived experimental models and the original tumors. Measurement : protein expression by liquid chromatography coupled with mass spectrometry Unit of measure : copy numbers for each protein Outcome measure 3 : tumor microenvironment profiles concordance between patient-derived experimental models and the original tumors. Measurement : microenvironment profiling by flow cytometry or immunohistochemistry Unit of measure : comparative enrichment for each immune cell subtype (CD4+ T-lymphocytes, CD8+ T-lymphocytes, CD25+ T-lymphocytes, macrophages) |
10 years
|
|
To understand the mechanisms underlying tumor evolution in each subtype of transformed B-cell lymphoma, with regard to both the characteristics of the tumor cell and its microenvironment.
時間枠:10 years
|
Outcome measure 1 : modification of gene expressions in malignant cells between the indolent stage, and the agressive transformation. Measurement : gene expression Measurement tool : whole transcriptome sequencing (RNA-seq) Unit of measure : transcripts rates Outcome measure 2 : modification of protein expressions in malignant cells between the indolent stage, and the agressive transformation. Measurement : protein expression Measurement tool : liquid chromatography coupled with mass spectrometry Unit of measure : copy numbers for each protein Outcome measure 3 : modification of tumor microenvironment between the indolent stage, and the agressive transformation. Measurement : microenvironment profiling Measurement tool : flow cytometry Unit of measure : comparative enrichment for each immune cell subtype (CD4+ T-lymphocytes, CD8+ T-lymphocytes, CD25+ T-lymphocytes, macrophages) |
10 years
|
協力者と研究者
出版物と役立つリンク
一般刊行物
- Ten Hacken E, Sewastianik T, Yin S, Hoffmann GB, Gruber M, Clement K, Penter L, Redd RA, Ruthen N, Hergalant S, Sholokhova A, Fell G, Parry EM, Broseus J, Guieze R, Lucas F, Hernandez-Sanchez M, Baranowski K, Southard J, Joyal H, Billington L, Regis FFD, Witten E, Uduman M, Knisbacher BA, Li S, Lyu H, Vaisitti T, Deaglio S, Inghirami G, Feugier P, Stilgenbauer S, Tausch E, Davids MS, Getz G, Livak KJ, Bozic I, Neuberg DS, Carrasco RD, Wu CJ. In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities. Blood Cancer Discov. 2023 Mar 1;4(2):150-169. doi: 10.1158/2643-3230.BCD-22-0082.
- Broseus J, Hergalant S, Vogt J, Tausch E, Kreuz M, Mottok A, Schneider C, Dartigeas C, Roos-Weil D, Quinquenel A, Moulin C, Ott G, Blanchet O, Tomowiak C, Lazarian G, Rouyer P, Chteinberg E, Bernhart SH, Tournilhac O, Gauchotte G, Lomazzi S, Chapiro E, Nguyen-Khac F, Chery C, Davi F, Hunault M, Houlgatte R, Rosenwald A, Delmer A, Meyre D, Bene MC, Thieblemont C, Lichter P, Ammerpohl O, Gueant JL; ICGC MMML-Seq Consortium; Guieze R, Martin-Subero JI, Cymbalista F, Feugier P, Siebert R, Stilgenbauer S. Molecular characterization of Richter syndrome identifies de novo diffuse large B-cell lymphomas with poor prognosis. Nat Commun. 2023 Jan 19;14(1):309. doi: 10.1038/s41467-022-34642-6.
- Parry EM, Lemvigh CK, Deng S, Dangle N, Ruthen N, Knisbacher BA, Broseus J, Hergalant S, Guieze R, Li S, Zhang W, Johnson C, Long JM, Yin S, Werner L, Anandappa A, Purroy N, Gohil S, Oliveira G, Bachireddy P, Shukla SA, Huang T, Khoury JD, Thakral B, Dickinson M, Tam C, Livak KJ, Getz G, Neuberg D, Feugier P, Kharchenko P, Wierda W, Olsen LR, Jain N, Wu CJ. ZNF683 marks a CD8+ T cell population associated with anti-tumor immunity following anti-PD-1 therapy for Richter syndrome. Cancer Cell. 2023 Oct 9;41(10):1803-1816.e8. doi: 10.1016/j.ccell.2023.08.013. Epub 2023 Sep 21.
- Parry EM, Leshchiner I, Guieze R, Johnson C, Tausch E, Parikh SA, Lemvigh C, Broseus J, Hergalant S, Messer C, Utro F, Levovitz C, Rhrissorrakrai K, Li L, Rosebrock D, Yin S, Deng S, Slowik K, Jacobs R, Huang T, Li S, Fell G, Redd R, Lin Z, Knisbacher BA, Livitz D, Schneider C, Ruthen N, Elagina L, Taylor-Weiner A, Persaud B, Martinez A, Fernandes SM, Purroy N, Anandappa AJ, Ma J, Hess J, Rassenti LZ, Kipps TJ, Jain N, Wierda W, Cymbalista F, Feugier P, Kay NE, Livak KJ, Danysh BP, Stewart C, Neuberg D, Davids MS, Brown JR, Parida L, Stilgenbauer S, Getz G, Wu CJ. Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome. Nat Med. 2023 Jan;29(1):158-169. doi: 10.1038/s41591-022-02113-6. Epub 2023 Jan 9.
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- 2024PI145
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Anonymized samples and clinical data will be shared with companion research teams.
Material and/or data transfer agreements will be signed between the University hopital of Nancy (promoter) and the associated research teams.
IPD 共有時間枠
Start date : inclusion date end date : end of the study (decembre 2036)
IPD 共有アクセス基準
Material and/or data transfer agreements will be signed between the University hopital of Nancy (promoter) and the associated research teams.
Data will be transfered with secured transfer protocols.
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- ICF
- CSR
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。